Methods of treating cancer using antibodies that immunospecifically bind to trail receptors

• US 7,361,341 B2
• Filed: 03/29/2006
• Issued: 04/22/2008
• Est. Priority Date: 05/25/2001
• Status: Expired due to Term

• Current Assignee: Human Genome Sciences Incorporated (GlaxoSmithKline PLC)
• Original Assignee: Human Genome Sciences Incorporated (GlaxoSmithKline PLC)
• Inventors: Vaughan, Tristan, Rosen, Craig A., Ruben, Steven M., Albert, Vivian R., Dobson, Claire, Salcedo, Theodora W.
• Primary Examiner(s): Blanchard; David J.
• Application Number:
  US11/391,384
• Publication Number:
  US 20060270837A1
• Time in Patent Office: 755 Days
• Field of Search: None
• US Class Current: 424/133.1
• CPC Class Codes: C07K 16/2878 against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/622 Single chain antibody (scFv)
• CPC Class Codes: C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor TR4.

Claims

1. A method of treating a TR4 expressing cancer comprising administering to an animal a proteasome inhibitor in combination with an isolaled antibody or fragment thereof comprising the amino acid sequence selected from the group consisting of:

(a) an amino acid sequence that is at least 95% identical to the VH and VL domains of SEQ ID NO;

42;

(b) an amino acid sequence that is at least 95% identical to the VH and VL domains of SEQ ID NQ;

43; and

(c) an amino acid sequence that is at least 95% identical to the VH and VL domains of SEQ ID NO;

47;

wherein said antibody or fragment thereof immunospecifically binds a TR4 protein selected from the group consisting of;

(i) a polypeptide having the amino acid sequence of any one of amino acid residues 1 to 468 of SEQ ID NO;

1;

amino acid residues 24 to 468 of SEQ ID NO;

1;

amino acid residues 24 to 238 of SEQ ID NO;

1; and

amino acid residues 109 to 240 of SEQ ID NO;

1;

(ii) a multimer of the polypeptide of (i);

(iii) the polypeptide of (i) expressed on the surface of a cell; and

(iv) the multimer of (ii) expressed on the surface of a cell.

2. The method of claim 1 wherein the proteasome inhibitor and the antibody are administered separately.

3. The method of claim 1 wherein the proteasome inhibitor is bortezomib.

4. The method of claim 1 wherein the cancer is multiple myeloma.

5. The method of claim 1 wherein the animal is a human.

6. The method of claim 1 wherein the proteasome inhibitor and the antibody are administered concomitantly.

7. The method of claim 1 wherein the proteasome inhibitor and the antibody are administered sequentially.

8. The method of claim 1 wherein said antibody or fragment thereof comprises a VH domain having the amino acid sequence of the VH domain of SEQ ID NO:

42 and a VL domain having the amino acid sequence of the VL domain of SEQ ID NO;

42.

9. The method of claim 1 wherein said antibody or fragment thereof comprises a VH domain having the amino acid sequence of the VH domain of SEQ ID NO:

43 and a VL domain having the amino acid sequence of the VL domain of SEQ ID NO;

43.

10. The method of claim 1 wherein said antibody or fragment thereof comprises a VH domain having the amino acid sequence of the VH domain of SEQ ID NO:

47 and a VL domain having the amino acid sequence of the VL domain of SEQ ID NO;

47.

11. The method of claim 1 wherein said antibody is expressed by the cell line of ATCC Deposit PTA-3570.

12. The method of claim 1 wherein said antibody is expressed by the cell line of ATCC Deposit PTA-3571.

13. The method of claim 1 wherein said antibody or fragment thereof is selected from the group consisting of:

(a) a whole immunoglobulin molecule;

(b) an scFv;

(c) a monoclonal antibody;

(d) a human antibody;

(e) a chimeric antibody;

(f) a Fab fragment;

(g) an Fab′

fragment;

(h) an F(ab′

)2;

(i) an Fv; and

(j) a disulfide linked Fv.

14. A method of inhibiting the growth of or killing TR4 expressing cells, comprising administering to an animal in which such inhibition of growth or killing of TR4 receptor expressing cells is desired, a proteasome inhibitor in combination with an isolated antibody or fragment thereof comprising the amino acid sequence selected from the group consisting of:

(a) an amino acid sequence that is at least 95% identical to the VH and VL domains of SEQ ID NO;

42;

(b) an amino acid sequence that is at least 95% identical to the VH and VL domains of SEQ ID NO;

43; and

(c) an amino acid sequence that is at least 95% identical to the VH and VL domains of SEQ ID NO;

47;

wherein said antibody or fragment thereof immunospecifically binds a TR4 protein selected from the group consisting of;

(i) a polypeptide having the amino acid sequence of any one of amino acid residues 1 to 468 of SEQ ID NO;

1;

amino acid residues 24 to 468 of SEQ ID NO;

1;

amino acid residues 24 to 238 of SEQ ID NO;

1; and

amino acid residues 109 to 240 of SEQ ID NO;

1;

(ii) a multimer of the polypeptide of (i);

(iii) the polypeptide of (i) expressed on the surface of a cell; and

(iv) the multimer of (ii) expressed on the surface of a cell.

15. The method of claim 14 wherein the proteasome inhibitor and the antibody are administered separately.

16. The method of claim 14 wherein the proteasome inhibitor is bortezomib.

17. The method of claim 14 wherein the cancer is multiple myeloma.

18. The method of claim 14 wherein the animal is a human.

19. The method of claim 14 wherein the proteasome inhibitor and the antibody are administered concomitantly.

20. The method of claim 14 wherein the proteasome inhibitor and the antibody are administered sequentially.

21. The method of claim 14 wherein said antibody or fragment thereof comprises a VH domain having the amino acid sequence of the VH domain of SEQ ID NO:

42 and a VL domain having the amino acid sequence of the VL domain of SEQ ID NO;

42.

22. The method of claim 14 wherein said antibody or fragment thereof comprises a VH domain having the amino acid sequence of the VH domain of SEQ ID NO:

43 and a VL domain having the amino acid sequence of the VL domain of SEQ ID NO;

43.

23. The method of claim 14 wherein said antibody or fragment thereof comprises a VH domain having the amino acid sequence of the VH domain of SEQ ID NO:

47 and a VL domain having the amino acid sequence of the VL domain of SEQ ID NO;

47.

24. The method of claim 14 wherein said antibody is expressed by the cell line of ATCC Deposit PTA-3570.

25. The method of claim 14 wherein said antibody is expressed by the cell line of ATCC Deposit PTA-3571.

26. The method of claim 14 wherein said antibody or fragment thereof is selected from the group consisting of:

(a) a whole immunoglobulin molecule;

(b) an scFv;

(c) a monoclonal antibody;

(d) a human antibody;

(e) a chimeric antibody;

(f) a Fab fragment;

(g) an Fab′

fragment;

(h) an F(ab′

)2;

(i) an Fv; and

(j) a disulfide linked Fv.

27. A method of treating a TR4 expressing cancer comprising administering to an animal a proteasome inhibitor in combination with an isolated antibody or fragment thereof comprising amino acid residues 26-35, 50-66, 99-107, 157-170, 186-192, and 225-234 of the amino acid sequence selected from the group consisting of:

(a) SEQ ID NO;

42;

(b) SEQ ID NO;

43; and

(c) SEQ ID NO;

47;

wherein said antibody or fragment thereof immunospecifically binds a TR4 protein selected from the group consisting of;

(i) a polypeptide having the amino acid sequence of any one of amino acid residues 1 to 468 of SEQ ID NO;

1;

amino acid residues 24 to 468 of SEQ ID NO;

1;

amino acid residues 24 to 238 of SEQ ID NO;

1; and

amino acid residues 109 to 240 of SEQ ID NO;

1;

(ii) a multimer of the polyeptide of (i);

(iii) the polypeptide of (i) expressed on the surface of a cell; and

(iv) the multimer of (ii) expressed on the surface of a cell.

28. A method of inhibiting the growth of or killing TR4 expressing cells, comprising administering to an animal in which such inhibition of growth or killing of TR4 receptor expressing cells is desired, a proteasome inhibitor in combination with an isolated antibody or fragment thereof comprising amino acid residues 26-35, 50-66, 99-107, 157-170, 186-192, and 225-234 of the amino acid sequence selected from the group consisting of:

(a) SEQ ID NO;

42;

(b) SEQ ID NO;

43; and

(c) SEQ ID NO;

47;

wherein said antibody or fragment thereof immunospecifically binds a TR4 protein selected from the group consisting of;

(i) a polypeptide having the amino acid sequence of anyone of amino acid residues 1 to 468 of SEQ ID NO;

1;

amino acid residues 24 to 468 of SEQ ID NO;

1;

amino acid residues 24 to 238 of SEQ ID NO;

1; and

amino acid residues 109 to 240 of SEQ ID NO;

1;

(ii) a multimer of the polypeptide of (i);

(iii) the polypeptide of (i) expressed on the surface of a cell; and

(iv) the multimer of (ii) expressed on the surface of a cell.